Lee, YS Lee, BH Park, SJ Kang, SB Rhim, H Park, JY Lee, JH Jeong, SW Lee, JY 2024-01-21T06:41:07Z 2024-01-21T06:41:07Z 2021-09-05 2004-07-05 0960-894X https://pubs.kist.re.kr/handle/201004/137413 For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS05001, IC50 = 0-9 muM) was nearly equipotent with mibefradil (IC50 = 0.84 muM) and inhibited LVA T-type Ca2+ channel with greater efficacy than HVA Ca2+ channel. (C) 2004 Elsevier Ltd. All rights reserved. English PERGAMON-ELSEVIER SCIENCE LTD CALCIUM-CHANNELS PHARMACOLOGICAL-PROPERTIES THALAMIC NEURONS IN-VITRO CARBODIIMIDE MIBEFRADIL INHIBITION THRESHOLD ALPHA-1H CONDUCTANCES 3,4-dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers Article 10.1016/j.bmcl.2004.04.090 1 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, v.14, no.13, pp.3379 - 3384 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14 13 3379 3384 scie scopus 000221998100001 2-s2.0-2942531077 Chemistry, Medicinal Chemistry, Organic Pharmacology & Pharmacy Chemistry Article CALCIUM-CHANNELS PHARMACOLOGICAL-PROPERTIES THALAMIC NEURONS IN-VITRO CARBODIIMIDE MIBEFRADIL INHIBITION THRESHOLD ALPHA-1H CONDUCTANCES 3,4-dihydroquinazolines T-type calcium channel blockers mibefradil